Shield Therapeutics plc (STX) - Total Liabilities

Latest as of June 2025: GBX76.96 Million GBX ≈ $9.36K USD

Based on the latest financial reports, Shield Therapeutics plc (STX) has total liabilities worth GBX76.96 Million GBX (≈ $9.36K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Shield Therapeutics plc to track the company's year-over-year net asset growth rate.

Shield Therapeutics plc - Total Liabilities Trend (2013–2024)

This chart illustrates how Shield Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. See Shield Therapeutics plc (STX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Shield Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Shield Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
DETALION GAMES SA ZY -10 F:9XJ	Germany	€592.89K
PCI-PAL PLC LSE:PCIP	UK	GBX17.02 Million
BlackRock Income and Growth Investment Trust plc LSE:BRIG	UK	GBX6.31 Million
Cora Gold Limited LSE:CORA	UK	GBX282.00K
Upsellon Brands Holdings Ltd TA:CHR	Israel	ILA2.01 Million
T-Bull S.A WAR:TBL	Poland	zł2.82 Million
CORELENS S.A. ZY -10 F:9GK	Germany	€20.84 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Shield Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see STX market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.83	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-5.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shield Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shield Therapeutics plc (2013–2024)

The table below shows the annual total liabilities of Shield Therapeutics plc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	GBX46.95 Million ≈ $5.71K	+77.25%
2023-12-31	GBX26.49 Million ≈ $3.22K	+59.11%
2022-12-31	GBX16.65 Million ≈ $2.03K	+392.51%
2021-12-31	GBX3.38 Million ≈ $411.25	+50.09%
2020-12-31	GBX2.25 Million ≈ $274.00	-46.05%
2019-12-31	GBX4.17 Million ≈ $507.86	+41.44%
2018-12-31	GBX2.95 Million ≈ $359.05	-21.58%
2017-12-31	GBX3.76 Million ≈ $457.85	-5.64%
2016-12-31	GBX3.99 Million ≈ $485.22	-81.45%
2015-12-31	GBX21.50 Million ≈ $2.62K	+11.48%
2014-12-31	GBX19.29 Million ≈ $2.35K	+139.66%
2013-12-31	GBX8.05 Million ≈ $979.21	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$519.78K

GBX4.27 Billion GBX

Market Cap Rank

#30902 Global

#917 in UK

Share Price

GBX4.00

Change (1 day)

+8.11%

52-Week Range

GBX3.70 - GBX12.20

All Time High

GBX185.02